Harmony Biosciences Holdings, Inc.(HRMY) Stock Research - Grey Stern Research
Loading...

Harmony Biosciences Holdings, Inc. (HRMY) Stock Analysis

$35.91 (-0.47%)

HRMY Financial Performance


Use the table below to view Harmony Biosciences Holdings, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $35.91 -
52 Week Low $23.43 -
52 Week High $41.61 -
Market Cap $2.0 Billion 10/22
Gross Margin 81% 7/22
Profit Margin 18% 2/22
EBITDA margin 12% 2/22
Q2 - 2024 Revenue $172.8 Million 1/22
Q2 - 2024 Earnings $31.8 Million 2/22
Q2 - 2024 Free Cash Flow $0 Million 3/22
Trailing 4 Quarters Revenue $656.1 Million 1/22
Trailing 4 Quarters Earnings $135.2 Million 2/22
Quarterly Earnings Growth -7% 8/22
Annual Earnings Growth 10% 7/22
Quarterly Revenue Growth 29% 6/22
Annual Revenue Growth 33% 4/22
Cash On Hand $317.3 Million 5/22
Short Term Debt $15.0 Million 2/22
Long Term Debt $171.4 Million 5/22

Harmony Biosciences Holdings, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Harmony Biosciences Holdings, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 15.15 3/22
PS 3.12 12/22
PB 3.80 11/22
PC 6.45 16/22
Liabilities to Equity 0.59 6/22
ROA 0.16 2/22
ROE 0.25 3/22
Current Ratio 2.68 15/22
Quick Ratio 1.08 19/22
Long Term Debt to Equity 0.32 6/22
Debt to Equity 0.35 6/22
Burn Rate -14.97 22/22
Cash to Cap 0.15 7/22
CCR 0.00 19/22
EV to EBITDA 89.77 1/22
EV to Revenue 2.92 12/22

Company Details

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

CEO: Mr. John Charles Jacobs M.B.A.

Website: https://www.harmonybiosciences.com

Address: 630 West Germantown Pike Plymouth Meeting, PA

Exchange: NASDAQ Global Market

Industry: Biotechnology

Harmony Biosciences Holdings, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Harmony Biosciences Holdings, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Protagonist Therapeutics, Inc. PTGX $2.8 Billion
Syndax Pharmaceuticals, Inc. SNDX $1.9 Billion
Fennec Pharmaceuticals Inc. FENC $116.6 Million
Verona Pharma plc VRNA $3.3 Billion
Gossamer Bio, Inc. GOSS $194.5 Million
IDEAYA Biosciences, Inc. IDYA $2.8 Billion
Replimune Group, Inc. REPL $854.0 Million
Revolution Medicines, Inc. RVMD $10.2 Billion
Keros Therapeutics, Inc. KROS $2.8 Billion
Lyra Therapeutics, Inc. LYRA $17.3 Million
Pliant Therapeutics, Inc. PLRX $883.0 Million
Inozyme Pharma, Inc. INZY $257.0 Million
Kronos Bio, Inc. KRON $52.6 Million
Cerevel Therapeutics Holdings, Inc. CERE $8.2 Billion
Edgewise Therapeutics, Inc. EWTX $3.3 Billion
Viridian Therapeutics, Inc. VRDN $2.0 Billion
Travere Therapeutics, Inc. TVTX $1.5 Billion
Nuvalent, Inc. NUVL $6.6 Billion
Janux Therapeutics, Inc. JANX $2.8 Billion
Nuvectis Pharma, Inc. NVCT $208.9 Million
Ventyx Biosciences, Inc. VTYX $151.9 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
HRMY Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 172.8 Million $31.8 Million
Q1 2024 $ 154.6 Million $38.3 Million
Q4 2023 $ 168.4 Million $26.6 Million
Q3 2023 $ 160.3 Million $38.5 Million
Q2 2023 $ 134.2 Million $34.3 Million
Q1 2023 $ 119.1 Million $29.5 Million
Q4 2022 $ 128.3 Million $48.5 Million
Q3 2022 $ 117.2 Million $87.9 Million

View All

HRMY Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $317.3 Million $858.4 Million $186.4 Million $538.6 Million
Q1 2024 $333.0 Million $847.0 Million $193.1 Million $515.4 Million
Q4 2023 $311.7 Million $811.4 Million $193.6 Million $467.0 Million
Q3 2023 $324.6 Million $777.8 Million $197.1 Million $481.3 Million
Q2 2023 $317.4 Million $760.2 Million $191.5 Million $485.2 Million
Q1 2023 $288.0 Million $715.1 Million $191.6 Million $443.0 Million
Q4 2022 $243.8 Million $673.9 Million $191.6 Million $402.8 Million
Q3 2022 $261.3 Million $643.5 Million $191.7 Million $343.9 Million

View All

HRMY Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $0 $0 $0
Q1 2024 $31.1 Million -$5,000 $21.3 Million
Q4 2023 $76.6 Million -$107,000 -$12.9 Million
Q3 2023 $63.1 Million $0 $7.2 Million
Q2 2023 $0 $0 $0
Q1 2023 $42.6 Million $0 $44.2 Million
Q4 2022 $66.9 Million $40.2 Million -$17.6 Million
Q3 2022 $95.1 Million $39.9 Million $24.8 Million

View All